OncoMatch/Clinical Trials/NCT07281924
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
Is NCT07281924 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Nivolumab and Relatlimab and Melphalan for metastatic melanoma.
Treatment: Nivolumab and Relatlimab · Melphalan — This study is being done to see if combining HEPZATO KIT™ with nivolumab and relatlimab (Opdualag™) in the first line setting in patients with metastatic melanoma with liver metastasis is safe, tolerable, and will have a synergistic effect leading to improved clinical outcomes compared to the historic cohort of patients with liver metastasis treated with combination immune checkpoint inhibitor therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Melanoma
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: (HEPZATO KIT, nivolumab and relatlimab (Opdualag))
Prior treatment with HEPZATO KIT™ or nivolumab and relatlimab (Opdualag™)
Lab requirements
Blood counts
Kidney function
Liver function
Demonstrate adequate organ function; all screening labs to be obtained within 28 days prior to registration.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UW Hospital and Clinics · Madison, Wisconsin
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07281924 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages